RxDoctor Payments Data

Jason Foreman

Clinical Cardiac Electrophysiology · Rockledge, FLNPI 1902096878

Payments from drug & device makers

$6,236in general payments, 2019–2025

Across 101 payments — averaging $61.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Boston Scientific$2K
  • Biosense Webster, Inc.$675
  • Abiomed$166
  • Elutia, Inc.$142
  • Pfizer$113
  • plus $400 from 8 others

What the payments were for

  • Travel & lodging$1,99832%
  • Food & beverage$4,23868%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,236 in reported general payments places this provider in the 10th percentile of 249 clinical cardiac electrophysiology providers in Florida.

See all clinical cardiac electrophysiology providers in Florida

Medicare billing

Part B allowed, 2024
$383,411
Medicare patients
1,724
Services billed
5,702

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban907$1,017,724
XareltoRivaroxaban214$240,839
EntrestoSacubitril/Valsartan78$109,282
MultaqDronedarone Hcl21$39,339
FarxigaDapagliflozin Propanediol38$31,877
Dofetilide35$12,333
CorlanorIvabradine Hcl19$12,198
Flecainide Acetate199$11,364
Disopyramide Phosphate12$5,209
Propafenone Hcl ErPropafenone Hcl19$5,084
Amiodarone Hcl244$4,804
Diltiazem 24hr Er (Cd)Diltiazem Hcl159$4,464
SotalolSotalol Hcl225$4,302
Metoprolol Succinate272$4,244
Carvedilol208$1,940

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$113$1,017,724907 claims
Johnson & JohnsonXarelto$43$240,839214 claims
NovartisEntresto$72$109,28278 claims
AmgenCorlanor$28$12,19819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 249 clinical cardiac electrophysiology providers in Florida.

Other clinical cardiac electrophysiology in Rockledge

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →